STAT3 and malignant colon neoplasm: GNVs, as therapeutic delivery vectors, transport biotinylated molecules and achieve targeted gene expression with minimal toxicity. The intranasal injection of GNVs encapsulated with the Stat3 inhibitor JSI-124 into GL26 tumor-bearing mice showed a significant inhibition of tumor growth. The intravenous administration of GNVs-folate (FA)-paclitaxel (PTX) showed enhanced targeted delivery and a significant reduction in tumor growth in the mouse CT26 colon cancer model and the human SW620 colon cancer SCID mouse model. No adverse reactions or major organ lesions were observed.